S&P 500   3,857.09 (-0.34%)
DOW   31,514.29 (+0.39%)
QQQ   312.86 (-1.74%)
AAPL   123.66 (-1.17%)
MSFT   229.07 (-2.05%)
FB   256.84 (-0.83%)
GOOGL   2,023.82 (-1.97%)
TSLA   678.98 (-1.09%)
AMZN   3,032.52 (-2.00%)
NVDA   520.17 (-3.00%)
BABA   236.44 (+0.86%)
CGC   33.77 (-4.20%)
GE   13.53 (+4.24%)
MU   91.02 (-0.08%)
NIO   42.65 (-1.48%)
AMD   82.08 (-2.44%)
T   28.50 (+0.99%)
F   12.35 (-1.59%)
ACB   10.62 (-3.72%)
DIS   194.02 (+0.04%)
BA   234.29 (+5.00%)
NFLX   525.19 (-4.13%)
PFE   34.08 (+1.70%)
S&P 500   3,857.09 (-0.34%)
DOW   31,514.29 (+0.39%)
QQQ   312.86 (-1.74%)
AAPL   123.66 (-1.17%)
MSFT   229.07 (-2.05%)
FB   256.84 (-0.83%)
GOOGL   2,023.82 (-1.97%)
TSLA   678.98 (-1.09%)
AMZN   3,032.52 (-2.00%)
NVDA   520.17 (-3.00%)
BABA   236.44 (+0.86%)
CGC   33.77 (-4.20%)
GE   13.53 (+4.24%)
MU   91.02 (-0.08%)
NIO   42.65 (-1.48%)
AMD   82.08 (-2.44%)
T   28.50 (+0.99%)
F   12.35 (-1.59%)
ACB   10.62 (-3.72%)
DIS   194.02 (+0.04%)
BA   234.29 (+5.00%)
NFLX   525.19 (-4.13%)
PFE   34.08 (+1.70%)
S&P 500   3,857.09 (-0.34%)
DOW   31,514.29 (+0.39%)
QQQ   312.86 (-1.74%)
AAPL   123.66 (-1.17%)
MSFT   229.07 (-2.05%)
FB   256.84 (-0.83%)
GOOGL   2,023.82 (-1.97%)
TSLA   678.98 (-1.09%)
AMZN   3,032.52 (-2.00%)
NVDA   520.17 (-3.00%)
BABA   236.44 (+0.86%)
CGC   33.77 (-4.20%)
GE   13.53 (+4.24%)
MU   91.02 (-0.08%)
NIO   42.65 (-1.48%)
AMD   82.08 (-2.44%)
T   28.50 (+0.99%)
F   12.35 (-1.59%)
ACB   10.62 (-3.72%)
DIS   194.02 (+0.04%)
BA   234.29 (+5.00%)
NFLX   525.19 (-4.13%)
PFE   34.08 (+1.70%)
S&P 500   3,857.09 (-0.34%)
DOW   31,514.29 (+0.39%)
QQQ   312.86 (-1.74%)
AAPL   123.66 (-1.17%)
MSFT   229.07 (-2.05%)
FB   256.84 (-0.83%)
GOOGL   2,023.82 (-1.97%)
TSLA   678.98 (-1.09%)
AMZN   3,032.52 (-2.00%)
NVDA   520.17 (-3.00%)
BABA   236.44 (+0.86%)
CGC   33.77 (-4.20%)
GE   13.53 (+4.24%)
MU   91.02 (-0.08%)
NIO   42.65 (-1.48%)
AMD   82.08 (-2.44%)
T   28.50 (+0.99%)
F   12.35 (-1.59%)
ACB   10.62 (-3.72%)
DIS   194.02 (+0.04%)
BA   234.29 (+5.00%)
NFLX   525.19 (-4.13%)
PFE   34.08 (+1.70%)
Log in
NASDAQ:BMRN

BioMarin Pharmaceutical Stock Forecast, Price & News

$76.22
-1.69 (-2.17 %)
(As of 03/3/2021 01:15 PM ET)
Add
Compare
Today's Range
$75.84
Now: $76.22
$77.58
50-Day Range
$77.43
MA: $83.85
$88.97
52-Week Range
$68.25
Now: $76.22
$131.95
Volume35,320 shs
Average Volume1.44 million shs
Market Capitalization$13.84 billion
P/E Ratio17.44
Dividend YieldN/A
Beta0.71
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide, a peptide therapeutic that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; and BMN 307, an AAV5 mediated gene therapy to normalize blood phenylalanine concentration levels in patients with phenylketonuria. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd.; and a preclinical collaboration and license agreement with DiNAQOR AG for the development of gene therapies to treat rare genetic cardiomyopathies. The company was founded in 1996 and is headquartered in San Rafael, California.
BioMarin Pharmaceutical logo

Headlines

BIOMARIN INVESTIGATION INITIATED BY FORMER...
February 27, 2021 |  benzinga.com
BioMarin (BMRN) Q4 Earnings Beat, 2021 Sales View Dull
February 26, 2021 |  finance.yahoo.com
Biomarin Pharmaceutical's Earnings Outlook
February 24, 2021 |  benzinga.com
ALXN vs. BMRN: Which Stock Is the Better Value Option?
February 11, 2021 |  finance.yahoo.com
Is Now A Good Time To Buy BioMarin Stock?
January 23, 2021 |  finance.yahoo.com
Stock Market News for Jan 12, 2021
January 12, 2021 |  finance.yahoo.com
Stock Alert: BioMarin Pharma Tumbles 8%
January 11, 2021 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BMRN
CUSIP09061G10
Phone415-506-6700
Employees3,001
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.70 billion
Cash Flow$0.59 per share
Book Value$17.38 per share

Profitability

Net Income$-23,850,000.00

Miscellaneous

Market Cap$13.84 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.86 out of 5 stars

Medical Sector

109th out of 1,969 stocks

Pharmaceutical Preparations Industry

45th out of 772 stocks

Analyst Opinion: 3.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
$76.22
-1.69 (-2.17 %)
(As of 03/3/2021 01:15 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions

Is BioMarin Pharmaceutical a buy right now?

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last twelve months. There are currently 8 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BioMarin Pharmaceutical stock.
View analyst ratings for BioMarin Pharmaceutical
or view top-rated stocks.

What stocks does MarketBeat like better than BioMarin Pharmaceutical?

Wall Street analysts have given BioMarin Pharmaceutical a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BioMarin Pharmaceutical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is BioMarin Pharmaceutical's next earnings date?

BioMarin Pharmaceutical is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for BioMarin Pharmaceutical
.

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced its quarterly earnings results on Thursday, February, 25th. The biotechnology company reported $0.12 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.18. BioMarin Pharmaceutical had a trailing twelve-month return on equity of 4.34% and a net margin of 45.74%.
View BioMarin Pharmaceutical's earnings history
.

How has BioMarin Pharmaceutical's stock price been impacted by Coronavirus?

BioMarin Pharmaceutical's stock was trading at $86.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BMRN shares have decreased by 12.0% and is now trading at $76.44.
View which stocks have been most impacted by COVID-19
.

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical updated its FY 2021 After-Hours earnings guidance on Thursday, February, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.75-1.85 billion, compared to the consensus revenue estimate of $1.91 billion.

What price target have analysts set for BMRN?

19 brokerages have issued 12 month price objectives for BioMarin Pharmaceutical's shares. Their forecasts range from $77.00 to $218.00. On average, they expect BioMarin Pharmaceutical's share price to reach $117.36 in the next twelve months. This suggests a possible upside of 53.5% from the stock's current price.
View analysts' price targets for BioMarin Pharmaceutical
or view top-rated stocks among Wall Street analysts.

Who are BioMarin Pharmaceutical's key executives?

BioMarin Pharmaceutical's management team includes the following people:
  • Mr. Jean-Jacques Bienaimé M.B.A., MBA, Chairman & CEO (Age 68, Pay $3.6M)
  • Mr. Jeffrey Robert Ajer, Exec. VP & Chief Commercial Officer (Age 59, Pay $1.17M)
  • Dr. Henry J. Fuchs, Pres of Worldwide R&D (Age 63, Pay $1.55M)
  • Mr. Brian R. Mueller, Exec. VP & CFO (Age 47)
  • Ms. Andrea L. Acosta, Group VP & Chief Accounting Officer (Age 42)
  • Dr. C. Greg Guyer Ph.D., CTO and Exec. VP of Global Manufacturing & Technical Operations
  • Mr. Lon Cardon Ph.D., Chief Scientific Strategy Officer
  • Traci McCarty, VP of Investor Relations
  • Mr. George Eric Davis, Exec. VP, Gen. Counsel & Sec. (Age 50)
  • Mr. Philip Lo Scalzo, Sr. VP & Chief Compliance Officer

What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO?

161 employees have rated BioMarin Pharmaceutical CEO Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among BioMarin Pharmaceutical's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of BioMarin Pharmaceutical's key competitors?

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX).

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (10.00%), Dodge & Cox (5.40%), Clearbridge Investments LLC (3.32%), Janus Henderson Group PLC (3.13%), UBS Asset Management Americas Inc. (1.36%) and Price T Rowe Associates Inc. MD (1.14%). Company insiders that own BioMarin Pharmaceutical stock include Brian Mueller, Daniel K Spiegelman, David E I Pyott, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, V Bryan Lawlis and Willard H Dere.
View institutional ownership trends for BioMarin Pharmaceutical
.

Which institutional investors are selling BioMarin Pharmaceutical stock?

BMRN stock was sold by a variety of institutional investors in the last quarter, including Nicholas Investment Partners LP, Russell Investments Group Ltd., Daiwa Securities Group Inc., Sumitomo Mitsui Trust Holdings Inc., Frontier Capital Management Co. LLC, Rhenman & Partners Asset Management AB, Nomura Asset Management Co. Ltd., and Public Employees Retirement Association of Colorado. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, V Bryan Lawlis, and Willard H Dere.
View insider buying and selling activity for BioMarin Pharmaceutical
or view top insider-selling stocks.

Which institutional investors are buying BioMarin Pharmaceutical stock?

BMRN stock was bought by a variety of institutional investors in the last quarter, including Dodge & Cox, Norges Bank, Parnassus Investments CA, Avidity Partners Management LP, Janus Henderson Group PLC, UBS Asset Management Americas Inc., Alliancebernstein L.P., and Price T Rowe Associates Inc. MD.
View insider buying and selling activity for BioMarin Pharmaceutical
or or view top insider-buying stocks.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioMarin Pharmaceutical's stock price today?

One share of BMRN stock can currently be purchased for approximately $76.44.

How much money does BioMarin Pharmaceutical make?

BioMarin Pharmaceutical has a market capitalization of $13.88 billion and generates $1.70 billion in revenue each year. The biotechnology company earns $-23,850,000.00 in net income (profit) each year or $0.07 on an earnings per share basis.

How many employees does BioMarin Pharmaceutical have?

BioMarin Pharmaceutical employs 3,001 workers across the globe.

What is BioMarin Pharmaceutical's official website?

The official website for BioMarin Pharmaceutical is www.bmrn.com.

Where are BioMarin Pharmaceutical's headquarters?

BioMarin Pharmaceutical is headquartered at 770 Lindaro Street, San Rafael CA, 94901.

How can I contact BioMarin Pharmaceutical?

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at 415-506-6700 or via email at [email protected]


This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.